Meet Us at UEG Week 2019

Taking GI Care Further Together

The digestive category has the second highest level of new cancer cases — and the second highest number of deaths. We’re committed to caring for the large, diverse population of GI patients with products to support them across the continuum of care.

Medtronic is here to help you meet the specific needs of individual patients along their continuum of care.

Scroll down for more information on our products and our recommended sessions throughout UEG Week 2019.

Artificial Intelligence in Colonoscopy

Expert panel discussion on GI GeniusTM @ UEG Week

If you would to attend the symposium, please register by clicking on the link below.

Visualize with confidence

Discover how the PillCamTM capsule endoscopy platform enables comprehensive GI tract imaging.

The PillCam™ capsule endoscopy platform uses innovative visualization technology to produce clear images of the digestive tract. This noninvasive platform allows physicians to detect GI abnormalities, monitor disease activity, and assess treatment efficacy.7

The Goal of Intervention is to prevent disease progression8

BarrxTM Endoscopic RFA Therapy

  • Barrx™ RFA has a better safety and side-effect profile than other ablative techniques9
  • RFA significantly eliminates Barrett’s tissue and reduces neoplastic progression to HGD/cancer compared to surveillance in confirmed LGD patients10
  • Radiofrequency ablation (RFA) has been shown in two RCT’s to reduce progression to Esophageal Adenocarcinoma (EAC)11,12

Enhanced Tissue Acquisition

Achieve more with the Beacon™ EUS Delivery System

The Beacon™ EUS delivery system features interchangeable FNA and FNB needles designed to support consistent and predictable acquisition of tissue samples with intact cellular architecture.13,14

The components of this innovative EUS delivery system are interchangeable, supporting greater efficiency15, while built-in safety features help protect healthcare staff from needle stick injury. And with advanced needles that help improve biopsy yield13,15, interventional endoscopists and pathologists can potentially increase diagnostic rates.14,15

Managing the risks of Procedural Sedation

Discover Capnography Monitoring

Moderate to deep sedation is very common during G.I. procedure, but associated with risk.

Some of the drugs usually administered have a potential respiratory depressant effect that may induce hypoventilation or airway obstruction and compromise the vital functions.

When changes to ventilation are not observed or noticed, the patient condition may deteriorate very rapidly, especially when the patient has significant comorbidities.

Recent clinical evidence and European guidelines detail how Capnography monitoring can help to manage the risk of Respiratory Compromise during G.I. Procedural Sedation.

Predictability. Now it's possible.

EmprintTM Ablation System, Powered by ThermosphereTM Technology

The EmprintTM ablation system powered by ThermosphereTM technology delivers that predictability. With three kinds of spatial energy control - thermal, field, and wavelenght - it produces precise spherical ablation zones. It's ablatiion you can count on. So the only thing to imagine is how it can transform your patient's lives.

Detect Early. Treat Early.

Endoflip™ Impedance Planimetry System

Measure pressure and dimensions in the esophagus, pylorus, and anal sphincters with a patient-friendly solution.

The Endoflip™ impedance planimetry system transforms the way you evaluate symptoms consistent with motility disorders and helps you minimize patient discomfort.16,17,18

This advanced imaging technology provides an internal view of the gastroesophageal (GE) junction during endoscopic and surgical procedures.

Real-time measurements of the pressure and dimensions in the esophagus, and other sphincters of the alimentary canal, help you identify major motility disorders.

  • 1. Dymedex Market Development Consulting, Strategic Market Assessment: Barrx-GI, October 30, 2014.

  • 2. Gerson L, Fidler J, Cave D, Leighton J. ACG Clinical Guideline: Diagnosis and management of small bowel bleeding. American Journal of Gastroenterology. 2015;110:1265-1287.

  • 3. Gralnek IM. Obscure-overt gastrointestinal bleeding. Gastroenterology. 2005;128:1424-30.

  • 4. Kaplan G. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology. 2015;12:720-727.

  • 5. SEER Cancer Statistics Factsheets: Pancreas Cancer. National Cancer Institute. Bethesda, MD,  http://seer.cancer.gov/statfacts/html/pancreas.html.

  • 6. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology. 2015;149(7):1731–1741.

  • 7. User Manual (DOC-2044-02 March 2013), page 3, 123.

  • 8. Whiteman DC, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-20.

  • 9. Fitzgerald RC, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42.

  • 10. Phoa et al, Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial JAMA 2014;311:1209-17.

  • 11. Smith CD et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 2007;21:560-569.

  • 12. Shaheen NJ al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. New England Journal of Medicine. 2009 May;360(22):2277-2288.

  • 13. DDW 2015 Presentations: #935. A Novel EUS-guided Liver Biopsy Needle is Superior to 19-G Core and FNA Needles: Examining the Effect of Needle Design, Number of Excursions, and Variable Suction Parameters on Histologic Yield. Schulman A, Thompson C, Chan W, Ryou M. #Tu1638. Initial experience with a novel EUS-guided core biopsy needle (SharkCore™): a North American multicenter study. DiMaio C, Kolb J, Benias P, et al. #Tu1648. Evaluating The Efficacy of a New FDA Approved EUS Core Biopsy Needle and Different Fine Needle Biopsy (FNB) Techniques To Yield The Best Core Specimen In a Live Porcine Model. Shivangi Kothari S, Kothari T, Zhou Z, et al.

  • 14. Based on product development testing data. Data on file. (See Report #1085 and Report #1090).

  • 15. Enestvedt B, Maranki, J, Makipour K, Mathur M, Haluszka O. Is Two Better Than One? a Comparison of EUS-FNA Efficiency of Single- vs Multi-Needle Platforms. Gastrointestinal Endoscopy. 2013;77(5S):AB179.

  • 16. Gyawali CP, Bredenoord AJ, Conklin JL, Fox M, Pandolfino JE, Peters JH, Roman S, Staiano A, Vaezi MF. Evaluation of esophageal motor function in clinical Practice. Neurogastroenterol Motil 2013;25(2):99-133.

  • 17. Carlson DA, Lin Z, Kahrilas PJ, Sternbach J, Donnan EN, Friesen L, Listernick Z, Mogni B, Pandolfino JE. The Functional Lumen Imaging Probe Detects Esophageal Contractility Not Observed With Manometry in Patients With Achalasia. Gastroenterology 2015;149(7):1742-1751.

  • 18. Carlson DA, Kahrilas PJ, Lin Z, Hirano I, Gonsalves N, Listernick Z, Ritter K, Tye M, Ponds FA, Wong I, Pandolfino JE. Evaluation of Esophageal Motility Utilizing the Functional Lumen Imaging Probe. Am J Gastroenterol 2016;111(12):1726-1735.